Last reviewed · How we verify
Hemorrhagic disease of the newborn due to vitamin K deficiency
Approved treatments
- Vitamin Mk 4
Menatetrenone works by acting as a vitamin K analog to promote blood clotting.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Hemorrhagic disease of the newborn due to vitamin K deficiency patent landscape — cliff calendar, originator estates, attackable patents
- Hemorrhagic disease of the newborn due to vitamin K deficiency treatment landscape brief
- Hemorrhagic disease of the newborn due to vitamin K deficiency treatment updates RSS
Frequently asked questions about Hemorrhagic disease of the newborn due to vitamin K deficiency
What drugs treat Hemorrhagic disease of the newborn due to vitamin K deficiency?
Tracked treatments include Vitamin Mk 4.
What is the treatment for Hemorrhagic disease of the newborn due to vitamin K deficiency?
Standard treatment for Hemorrhagic disease of the newborn due to vitamin K deficiency includes Vitamin Mk 4. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Hemorrhagic disease of the newborn due to vitamin K deficiency patent cliff · Hemorrhagic disease of the newborn due to vitamin K deficiency CI report
- Treatment: Vitamin Mk 4
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing